NASDAQ · ZLAB
Healthcare · Biotechnology
$25.58
Down-$0.27 (-1.06%)
Updated Oct 7, 2026, 8:24 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ZLAB
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
ZLAB closed at $25.58 after 21 trading sessions, up 0.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $26.80 | $26.92 | $25.51 | $25.58 | 1.21M |
| Oct 5, 2026 | $24.44 | $25.65 | $24.33 | $25.62 | 787.36K |
| Oct 2, 2026 | $24.86 | $24.86 | $23.71 | $24.33 | 951.85K |
| Oct 1, 2026 | $26.30 | $26.52 | $25.41 | $25.50 | 545.23K |
| Sep 30, 2026 | $26.35 | $26.68 | $26.00 | $26.34 | 830.83K |
| Sep 29, 2026 | $26.22 | $26.22 | $25.365 | $25.93 | 549.1K |
| Sep 28, 2026 | $25.41 | $26.50 | $25.06 | $25.69 | 884.78K |
| Sep 25, 2026 | $25.21 | $25.54 | $24.945 | $24.98 | 299.9K |
| Sep 24, 2026 | $25.42 | $25.42 | $24.8051 | $25.28 | 585.28K |
| Sep 23, 2026 | $26.51 | $26.80 | $26.29 | $26.44 | 791.64K |
| Sep 22, 2026 | $26.885 | $27.045 | $26.37 | $26.41 | 996.56K |
| Sep 21, 2026 | $26.64 | $26.72 | $26.16 | $26.43 | 1.18M |
| Sep 18, 2026 | $26.26 | $27.14 | $25.60 | $25.70 | 887.48K |
| Sep 17, 2026 | $25.245 | $26.07 | $25.025 | $25.81 | 673.11K |
| Sep 16, 2026 | $24.90 | $25.32 | $24.42 | $24.67 | 1.16M |
| Sep 15, 2026 | $24.485 | $25.00 | $24.485 | $24.80 | 937.28K |
| Sep 14, 2026 | $24.30 | $24.65 | $23.89 | $24.58 | 1.16M |
| Sep 11, 2026 | $24.41 | $24.615 | $24.06 | $24.14 | 663.51K |
| Sep 10, 2026 | $24.01 | $24.66 | $23.64 | $24.17 | 1.61M |
| Sep 9, 2026 | $25.45 | $25.57 | $25.05 | $25.08 | 491.7K |
| Sep 8, 2026 | $25.74 | $26.50 | $25.37 | $25.41 | 711.75K |
The latest Smart Investors Daily articles mentioning ZLAB.
Company
Market Activity
Research & News
ZLAB research
Company profile and research snapshot.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2020 | SVB Leerink | Outperform | — |
| Dec 30, 2019 | Citigroup | Buy | — |
| Sep 4, 2019 | China Renaissance | Buy | — |
| Jul 5, 2019 | Macquarie | Outperform | — |
| Jan 29, 2019 | Credit Suisse | Outperform | — |
No generated briefing is available yet.
Benzinga · Oct 5, 2026
Zai Lab (NASDAQ:ZLAB) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings
Yahoo · Oct 4, 2026
ESMO data disclosure puts Zai Lab’s early lung cancer program in focus Zai Lab (ZLAB) has put fresh attention on its pipeline after confirming that global Phase 1b/1c data for zocilurtatug pelitecan in extensive-stage small cell lung cancer will appear at the ESMO Congress 2026. The ESMO update lands after a mixed period for Zai Lab, with the share price down 7.24% over the past 30 days, yet up 27.52% on a 90 day basis and 40.39% year to date, while the 1 year total shareholder return is...
Yahoo · Sep 29, 2026
SHANGHAI & CAMBRIDGE, Mass., September 29, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) will be shared for the first time at the European Society for Medical Oncology (ESMO) Congress 2026 taking place October 23-27, 2026, in Madrid.
Benzinga · Sep 28, 2026
Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and outperformed for the
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ZLAB.
